Manuscripts and Publications

Filters: Keyword is Anti-HIV Agents  [Clear All Filters]
2020
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
Naar S, Robles G, MacDonell KKolmodin, Dinaj-Koci V, Simpson KN, Lam P, Parsons JT, K Sizemore M, Starks TJ.  2020.  Comparative Effectiveness of Community-Based vs Clinic-Based Healthy Choices Motivational Intervention to Improve Health Behaviors Among Youth Living With HIV: A Randomized Clinical Trial.. JAMA Netw Open. 3(8):e2014650.
Christodoulou J, Abdalian SEllen, Jones ASK, Christodoulou G, Pentoney SL, Rotheram-Borus MJane.  2020.  Crystal Clear with Active Visualization: Understanding Medication Adherence Among Youth Living with HIV.. AIDS Behav. 24(4):1207-1211.
Sullivan PS, Mouhanna F, Mera R, Pembleton E, Castel AD, Jaggi C, Jones J, Kramer MR, McGuinness P, McCallister S et al..  2020.  Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.. Ann Epidemiol. 44:16-30.
Siegler AJ, C Mehta C, Mouhanna F, Giler RMera, Castel A, Pembleton E, Jaggi C, Jones J, Kramer MR, McGuinness P et al..  2020.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.. Ann Epidemiol. 45:24-31.e3.
Siegler AJ, Wiatrek S, Mouhanna F, K Amico R, Dominguez K, Jones J, Patel RR, Mena LA, Mayer KH.  2020.  Validation of the HIV Pre-exposure Prophylaxis Stigma Scale: Performance of Likert and Semantic Differential Scale Versions.. AIDS Behav. 24(9):2637-2649.
2016
Mullins TLKowalczy, Zimet G, Lally M, Kahn JA.  2016.  Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.. AIDS Patient Care STDS. 30(7):339-48.
Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, E Patton D, Ren W, Thornton SE, Major-Wilson HO, Puga AM et al..  2016.  Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
Dowshen N, Matone M, Luan X, Lee S, Belzer M, Fernandez MIsabel, Rubin D.  2016.  Behavioral and Health Outcomes for HIV+ Young Transgender Women (YTW) Linked To and Engaged in Medical Care.. LGBT Health. 3(2):162-7.
Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, Gardner EM, Liu A, Glidden DV, Grant R et al..  2016.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
Gross IMoses, Hosek S, Richards MHeather, M Fernández I.  2016.  Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
Tanner AE, Philbin MM, Duval A, Ellen J, Kapogiannis B, J Fortenberry D.  2016.  Transitioning HIV-Positive Adolescents to Adult Care: Lessons Learned From Twelve Adolescent Medicine Clinics.. J Pediatr Nurs. 31(5):537-43.